Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis

Nov 15, 2018Cell death & disease

Low oxygen blocks cell death in mitochondria, leading to resistance to temozolomide treatment through the miR-26a/Bad/Bax pathway

AI simplified

Abstract

Hypoxia in glioblastoma multiforme is linked to TMZ resistance through HIF-1α-mediated upregulation.

  • Hypoxia induces a protective response in glioblastoma cells, which may contribute to resistance against temozolomide.
  • The HIF-1α/miR-26a axis appears to enhance temozolomide resistance by preventing mitochondrial dysfunction.
  • In clinical samples, higher levels of miR-26a are associated with increased HIF-1α and lower levels of .
  • Bax and Bad levels negatively correlate with miR-26a expression and glioblastoma progression.

AI simplified

Key numbers

γH2AX levels increased in TMZ-treated U87MG cells
Increase in γH2AX Levels
Comparison of γH2AX levels in normoxic vs. hypoxic TMZ-treated cells
U87MG/ with Bax/Bad overexpression showed a higher survival rate
Higher Survival Rate
Survival rates of mice with different tumor cell lines after TMZ treatment

Full Text

What this is

  • Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options.
  • Temozolomide (TMZ) is the standard chemotherapy, but hypoxia in tumors contributes to treatment resistance.
  • This research investigates how hypoxia-induced upregulation protects GBM cells from apoptosis and enhances TMZ resistance.

Essence

  • Hypoxia enhances TMZ resistance in GBM by upregulating , which inhibits pro-apoptotic factors , thereby protecting mitochondrial function.

Key takeaways

  • Hypoxia reduces DNA damage in GBM cells during TMZ treatment. TMZ treatment increases γH2AX levels, but hypoxia diminishes this effect, suggesting a protective role against apoptosis.
  • is identified as a key regulator of TMZ resistance. It targets , preventing their pro-apoptotic functions, which contributes to enhanced survival of GBM cells under hypoxic conditions.
  • In vivo studies show that overexpression of increases TMZ sensitivity and improves survival rates in mouse models. This indicates that manipulating the /Bax/Bad axis could be a therapeutic strategy.

Caveats

  • The study primarily focuses on cellular and animal models, which may not fully replicate human GBM responses to TMZ treatment.
  • Further research is needed to explore the clinical implications of targeting the /Bax/Bad axis in GBM therapy.

Definitions

  • miR-26a: An 18–22 nucleotide microRNA that regulates gene expression, implicated in tumor progression and chemotherapy resistance.
  • HIF-1α: A transcription factor that responds to hypoxia, promoting survival and adaptation of cancer cells in low-oxygen environments.
  • Bax and Bad: Pro-apoptotic proteins that promote mitochondrial dysfunction and apoptosis; their regulation is critical in cancer cell survival.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free